Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Adapted Physical Activity for Persistent Fatigue in Patients With Inflammatory Bowel Disease in Remission (cAPAble)

8 september 2026 uppdaterad av: University Hospital, Grenoble

Impact of Adapted Physical Activity on Persistent Fatigue in Patients With Inflammatory Bowel Disease in Remission

The cAPAble study aims to evaluate the impact of an adapted physical activity program on persistent fatigue in patients with inflammatory bowel disease in remission. This multicenter randomized study will include 120 participants. Participants will be randomly assigned to either a 6-month adapted physical activity program or usual care. Fatigue will be assessed using the FACIT-F questionnaire at 6 months.

Studieöversikt

Detaljerad beskrivning

Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, are chronic conditions that can affect patients' daily lives even when the disease is in remission. Persistent fatigue is a common and disabling symptom that may remain despite control of intestinal inflammation.

The cAPAble study will evaluate whether an adapted physical activity (APA) program can help reduce persistent fatigue in patients with IBD in remission. This is a multicenter randomized interventional study. Participants will be randomly assigned to an adapted physical activity program or usual care.

The APA program is designed to be adapted to each participant's physical abilities and needs and will be delivered over 6 months. The program aims to progressively increase physical activity and support participants in maintaining regular physical activity in their daily lives.

The main purpose of the study is to determine whether participation in the APA program improves persistent fatigue. The study will also explore potential effects on physical activity, quality of life, psychological well-being and other aspects of participants' health and daily functioning.

Participants will be followed throughout the study according to the protocol, with assessments performed at predefined time points using validated questionnaires and other study assessments. The results of the study may help improve the management of persistent fatigue in people with IBD in remission and contribute to the development of supportive non-drug approaches for these patients.

Studietyp

Interventionell

Inskrivning (Beräknad)

120

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Beskrivning

Inclusion Criteria:

  1. Patients with inflammatory bowel disease (IBD) in clinical and biological remission (CRP/fecal calprotectin) for more than 6 months:

    • Remission according to PRO2 (Patient-Reported Outcome): liquid stool frequency ≤2/day and abdominal pain score ≤1 for Crohn's disease; stool frequency score ≤1 and rectal bleeding score = 0 for ulcerative colitis.
    • CRP <5 mg/L.
    • Fecal calprotectin <250 µg/g.
  2. Patients with significant fatigue (FACIT-F score ≤40) persisting for at least 3 months before inclusion, confirmed by two successive FACIT-F questionnaire assessments: the first at the screening visit (M-3), after obtaining informed consent, serving as the baseline value, and the second at the inclusion visit (M0), confirming persistence of fatigue for at least 3 months.
  3. Adults aged 18 years or older.
  4. Medical certificate confirming fitness to participate in physical activity. If the participant does not have a recent certificate dated within the previous 3 months, a specific consultation with the treating physician will be required. This consultation will be covered by the sponsor.

Exclusion Criteria:

  1. Another identified cause of fatigue based on the first-line assessment performed in this context (complete blood count, liver function tests, CRP, blood electrolyte panel, serum creatinine, iron studies, folate, vitamin B12, TSH, fasting blood glucose).
  2. Unstable cardiovascular or respiratory disease.
  3. Patients already meeting the WHO physical activity recommendations before inclusion (IPAQ score ≥1500).
  4. Current pregnancy or pregnancy planned during the study period.
  5. Inability, for technical or other reasons, to connect to the Internet for telemonitoring and/or telerehabilitation.
  6. Planned surgery requiring hospitalization.
  7. Refusal to participate.
  8. Persons under legal guardianship or deprived of liberty.
  9. Uncontrolled diagnosed psychiatric disorder.
  10. Participant currently in an exclusion period for another clinical study.
  11. Participant who cannot be contacted in case of an emergency.
  12. Any surgery planned during the first 6 months of the study that requires hospitalization.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Stödjande vård
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Adapted Physical Activity
A 6-month adapted physical activity program tailored to the participant's individual physical abilities and needs.
A 6-month adapted physical activity program tailored to each participant's physical abilities and individual needs. The program consists of 12 one-hour sessions delivered every two weeks, followed by 2 months of telephone follow-up to support participants in maintaining regular physical activity.
Övrig: Usual Care
Participants will receive usual care according to standard clinical practice.
Participants will receive usual care according to standard clinical practice.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Mean Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) score at 6 months.
Tidsram: at 6 months
Mean Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) score in each study arm at 6 months. The FACIT-F scale ranges from 0 to 52, with higher scores indicating less fatigue and better quality of life.
at 6 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Fatigue assessed by the FACIT-Fatigue (FACIT-F) score at 3 and 12 months
Tidsram: At 3 months and 12 months
The FACIT-Fatigue subscale is a 13-item self-administered questionnaire. The total score ranges from 0 to 52; a higher score indicates less fatigue (better outcome). Mean scores are compared between the adapted physical activity arm and the standard care arm.
At 3 months and 12 months
Physical condition assessed by Body weight
Tidsram: At 6 months and 12 months
Body weight (kg) - mean values are compared between the adapted physical activity arm and the standard care arm.
At 6 months and 12 months
Physical condition assessed by body mass index
Tidsram: At 6 months and 12 months
Body mass index (kg/m²) - Mean values are compared between the adapted physical activity arm and the standard care arm.
At 6 months and 12 months
Physical condition assessed by waist circumference
Tidsram: At 6 months and 12 months
Waist circumference (cm) - Mean values are compared between the adapted physical activity arm and the standard care arm.
At 6 months and 12 months
Physical condition assessed by handgrip strength
Tidsram: At 6 months and 12 months
Handgrip strength measured by dynamometer (kg) - Mean values are compared between the adapted physical activity arm and the standard care arm.
At 6 months and 12 months
Health care resource use
Tidsram: At 6 months and 12 months
Number of participants with at least one of the following events, collected using a study-specific health care use questionnaire: hospitalisation, corticosteroid course, change in inflammatory bowel disease therapy, consultation with a general practitioner, consultation with a psychologist, and use of complementary or alternative medicine. Compared between the adapted physical activity arm and the standard care arm.
At 6 months and 12 months
Health care resource use
Tidsram: At 6 months and 12 months
Proportion of participants with at least one of the following events, collected using a study-specific health care use questionnaire: hospitalisation, corticosteroid course, change in inflammatory bowel disease therapy, consultation with a general practitioner, consultation with a psychologist, and use of complementary or alternative medicine. Compared between the adapted physical activity arm and the standard care arm.
At 6 months and 12 months
Biological disease activity assessed by C-reactive protein (mg/L)
Tidsram: At 3 months, 6 months and 12 months
C-reactive protein (mg/L) - a higher value indicates greater disease activity. Mean values are compared between the adapted physical activity arm and the standard care arm.
At 3 months, 6 months and 12 months
Biological disease activity assessed by Faecal calprotectin (µg/g)
Tidsram: At 3 months, 6 months and 12 months
Faecal calprotectin (µg/g) - a higher value indicates greater disease activity. Mean values are compared between the adapted physical activity arm and the standard care arm.
At 3 months, 6 months and 12 months
Physical activity level assessed by the International Physical Activity Questionnaire (IPAQ)
Tidsram: At 3 months, 6 months and 12
The International Physical Activity Questionnaire (IPAQ) is a self-administered questionnaire; physical activity is expressed in MET-minutes per week. A higher value indicates a higher level of physical activity. Mean values are compared between the adapted physical activity arm and the standard care arm.
At 3 months, 6 months and 12
Functional capacity assessed by the 6-minute walk test
Tidsram: At 6 months and 12 months
Maximal distance walked during the 6-minute walk test, expressed in metres. A greater distance indicates better functional capacity. Mean values are compared between the adapted physical activity arm and the standard care arm.
At 6 months and 12 months
Correlation between a fatigue visual analogue scale and the FACIT-Fatigue score
Tidsram: At 3 months, 6 months and 12 months
Correlation coefficient between the fatigue visual analogue scale (VAS-F, scored from 0 to 10, a higher score indicating more fatigue) and the FACIT-Fatigue score (scored from 0 to 52, a higher score indicating less fatigue), at each assessment time point. This outcome measure is assessed in the whole study population and is not a between-arm comparison.
At 3 months, 6 months and 12 months
Quality of life assessed by the Inflammatory Bowel Disease Disability Index (IBD-Disk)
Tidsram: At 3 months, 6 months and 12 months
The Inflammatory Bowel Disease Disability Index (IBD-Disk) is a 10-item self-administered instrument. Each item is rated on a numerical scale from 0 to 10, resulting in a total score ranging from 0 to 100. Higher scores indicate greater disability and poorer quality of life. Mean IBD-Disk scores will be compared between the adapted physical activity arm and the standard care arm.
At 3 months, 6 months and 12 months
State anxiety assessed by the State-Trait Anxiety Inventory - State subscale (STAI-State)
Tidsram: At 6 months and 12 months
The State-Trait Anxiety Inventory - State subscale (STAI-State) is a 20-item self-administered instrument assessing current state anxiety. The total score ranges from 20 to 80, with higher scores indicating greater state anxiety. Mean STAI-State scores will be compared between the adapted physical activity arm and the standard care arm.
At 6 months and 12 months
Depressive symptoms assessed by the Patient Health Questionnaire-9 (PHQ-9)
Tidsram: At 6 months and 12 months
The Patient Health Questionnaire-9 (PHQ-9) is a 9-item self-administered instrument assessing depressive symptoms. The total score ranges from 0 to 27, with higher scores indicating more severe depressive symptoms. Mean PHQ-9 scores will be compared between the adapted physical activity arm and the standard care arm.
At 6 months and 12 months
Clinical disease activity assessed by the Patient-Reported Outcomes 2 (PRO2)
Tidsram: At 3 months, 6 months and 12 months
The Patient-Reported Outcomes 2 (PRO2) is a patient-reported measure of ulcerative colitis disease activity based on stool frequency and rectal bleeding. The total score ranges from 0 to 6, with higher scores indicating greater clinical disease activity. Mean PRO2 scores will be compared between the adapted physical activity arm and the standard care arm.
At 3 months, 6 months and 12 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 juni 2027

Primärt slutförande (Beräknad)

1 december 2028

Avslutad studie (Beräknad)

1 februari 2030

Studieregistreringsdatum

Först inskickad

31 augusti 2026

Först inskickad som uppfyllde QC-kriterierna

31 augusti 2026

Första postat (Faktisk)

4 september 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

11 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

8 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera